Palisade Bio (NASDAQ:PALI – Get Free Report) and Oculis (NASDAQ:OCS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.
Institutional and Insider Ownership
11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Palisade Bio and Oculis”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Palisade Bio | $250,000.00 | 808.61 | -$16.78 million | ($0.48) | -2.42 |
| Oculis | $1.45 million | 330.29 | -$119.44 million | ($1.74) | -4.75 |
Palisade Bio has higher earnings, but lower revenue than Oculis. Oculis is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Palisade Bio has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Profitability
This table compares Palisade Bio and Oculis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palisade Bio | N/A | -33.47% | -31.79% |
| Oculis | -6,777.18% | -42.61% | -35.23% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Palisade Bio and Oculis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palisade Bio | 1 | 0 | 8 | 2 | 3.00 |
| Oculis | 1 | 0 | 9 | 0 | 2.80 |
Palisade Bio currently has a consensus target price of $9.29, indicating a potential upside of 700.49%. Oculis has a consensus target price of $39.44, indicating a potential upside of 377.54%. Given Palisade Bio’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Palisade Bio is more favorable than Oculis.
Summary
Palisade Bio beats Oculis on 12 of the 15 factors compared between the two stocks.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
